166889 Using the FCA FCTC Monitor data to assess country progress on selected articles

Monday, November 5, 2007: 11:10 AM

Ana Navas-Acien, PhD , Department of Environmental Health, Johns Hokpins Bloomberg School of Public Health, Baltimore, MD
This presentation will report on the data collected from 27 of the first 41 countries that ratified or acceded to the FCTC. The collected data assess the progress each country has made in implementing key articles of the convention, including policies regarding price and taxation (article 6); protection from exposure to tobacco smoke (article 8); packaging and labeling of tobacco products

(article 11); tobacco advertising, promotion, and sponsorship (article 13); treatments for tobacco dependence (article 14); and illicit

trade of tobacco products (article 15). All 27 participating countries have implemented national price and tax policies on tobacco

products, but many are not using price and taxation to their maximum effectiveness. Less than half of the countries have price and tax policies motivated by reducing tobacco consumption. Most of the 27 participating countries are still not effectively protecting all their population from exposure to tobacco smoke. Only two countries, New Zealand and Uruguay, are described as having a national smoking ban in all indoor workplaces, public transport, and public places, without exceptions, and with high levels of compliance and enforcement. Twenty-four countries have a legislated

requirements for health warnings on tobacco packages. Among these, eight do not yet have warnings large enough to meet the FCTC's 30 percent minimum standard, but eight meet or exceed the recommended 50 percent standard.

Learning Objectives:
1. Gain understanding of the Framework Convention for Tobacco Control (FCTC). 2. Gain understanding of the role of civil society in the implementation of the FCTC. 3. Be able to determine how countries have implemented the FCTC

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.